Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kevin Barber

Ophthalmology Deland, FL Medical Doctor

NPI 1184612269 CMS profile 52964

1592 South State Road 15-A, Deland, FL 32720

Open in the dashboard

General payments

$56,250

152 records reported · program years 2019–2025

Research payments

$4,161

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,095,818 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Kevin Barber of Deland, FL is reported in the CMS Open Payments database as having received $56,250 across 152 general payments and $4,161 in research payments paid to them. Separately, studies naming them as principal investigator received $1,095,818 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $653 2
2024 General $19,976 20
2023 General $2,047 14
2022 General $6,532 20
2021 General $9,940 33
2020 General $7,149 28
2020 Research $4,161 1
2019 General $9,952 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Barber
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Kevin Barber were reported at $653. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Kevin Barber Ophthalmology median Middle half National median
2019 $9,952 $258 $104–$655 $163
2020 $7,149 $126 $45–$321 $114
2021 $9,940 $205 $76–$534 $132
2022 $6,532 $266 $100–$678 $149
2023 $2,047 $308 $117–$745 $160
2024 $19,976 $340 $127–$846 $164
2025 $653 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $20,466 74 payments
  2. Glaukos Corporation $18,394 6 payments
  3. Alcon Research LLC $15,706 19 payments
  4. Beaver-Visitec International, Inc. $700 1 payment
  5. New World Medical,Inc. $439 14 payments
  6. Allergan Inc. $326 26 payments
  7. Horizon Therapeutics plc $56 3 payments
  8. Sun Pharmaceutical Industries Inc. $44 2 payments
  9. Sight Sciences, Inc. $41 2 payments
  10. Bausch & Lomb, a division of Bausch Health US, LLC $22 1 payment
  11. Other $56 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $47,283 30 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,780 3 payments
  3. Food and Beverage $3,541 112 payments
  4. Travel and Lodging $1,600 6 payments
  5. Gift $45 1 payment
Products named General payments · program years 2019–2025
  1. iDose $18,223 2 payments
  2. NGENUITY $12,674 23 payments
  3. ORA $4,614 9 payments
  4. AcrySof $3,259 7 payments
  5. AcrySof IQ PanOptix $3,057 7 payments
  6. SMART Suite $2,100 2 payments
  7. LenSx $1,645 5 payments
  8. Centurion Ophthalmology $1,171 3 payments
  9. Centurion Ophthalmology $1,168 5 payments
  10. Luxor $350 1 payment
  11. Other $2,494 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Glaukos Corporation $4,161 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

61

Median for Ophthalmology: 891

Drug cost

$4,952

Median for Ophthalmology: $68,233

Branded share of claims

23%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyzulta Latanoprostene Bunod Brand 14 $4,348
Prednisolone Acetate Generic 11 $306
Latanoprost Generic 22 $189
Timolol Maleate Generic 14 $109

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$137,521

Medicare's payments for the services billed

Medicare patients

230

Average age 75

Services billed

754

154 women, 76 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 49%
Ischemic heart disease 27%
Diabetes 24%
Atrial fibrillation 20%
Chronic kidney disease 20%
COPD 19%
Osteoporosis 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

153 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record